Meeting
2021 ASCO Annual Meeting
Preventive HIPEC in combination with perioperative FLOT versus FLOT alone for resectable diffuse type gastric and gastroesophageal junction type II/III adenocarcinoma: The phase III “PREVENT” trial of the AIO /CAOGI /ACO.
Authors
Thorsten Oliver Goetze
University Cancer Center Frankfurt, Institut für Klinisch-Onkologische Forschung and Institut für Klinische Krebsforschung IKF GmbH am Krankenhaus Nordwest, Frankfurt, Germany
Thorsten Oliver Goetze , Pompiliu Piso , Sylvie Lorenzen , Ulli Simone Bankstahl , Marcin Ostrzyzek , Claudia Pauligk , Timursah Habibzade , Daniel Reim , Wolf Otto Bechstein , Alfred Königsrainer , Stefan Paul Mönig , Beate Rau , Matthias Schwarzbach , Salah-Eddin Al-Batran
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary
Track
Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary
Sub Track
Esophageal or Gastric Cancer
Clinical Trial Registration Number
NCT04447352
Citation
J Clin Oncol 39, 2021 (suppl 15; abstr TPS4149)
DOI
10.1200/JCO.2021.39.15_suppl.TPS4149
Abstract #
TPS4149
Poster Bd #
Online Only
Abstract Disclosures
Similar Posters
Poster
2024 ASCO Gastrointestinal Cancers Symposium
Safety of preventive HIPEC in combination with perioperative FLOT versus FLOT alone for resectable diffuse type gastric and gastroesophageal junction type II/III adenocarcinoma: An interim safety analysis from the phase III PREVENT trial of the AIO/CAOGI/ACO.
First Author: Thorsten Goetze
Poster
2024 ASCO Gastrointestinal Cancers Symposium
Randomized phase II study comparing neoadjuvant FLOT versus DOS for patients with type 4 or large type 3 gastric cancer (JCOG2204).
First Author: Izuma Nakayama
Poster
2023 ASCO Gastrointestinal Cancers Symposium
Safety and short-term efficacy of neoadjuvant FLOT therapy in patients with resectable esophageal squamous cell carcinoma.
First Author: Yuri Yoshinami
Poster
2021 ASCO Annual Meeting
MATTERHORN: Efficacy and safety of neoadjuvant-adjuvant durvalumab and FLOT chemotherapy in resectable gastric and gastroesophageal junction cancer—A randomized, double-blind, placebo-controlled, phase 3 study.
First Author: Yelena Y. Janjigian